SRR934861
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.348226018396845
- age_years
- 56
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.614
- E2F_TARGETS+0.608
- INTERFERON_ALPHA_RESPONSE+0.581
- MYC_TARGETS_V2+0.520
- MYC_TARGETS_V1+0.501
- INTERFERON_GAMMA_RESPONSE+0.496
- MITOTIC_SPINDLE+0.479
- TGF_BETA_SIGNALING+0.470
- NOTCH_SIGNALING+0.469
- MTORC1_SIGNALING+0.429
Top 10 suppressed
- KRAS_SIGNALING_DN-0.445
- PANCREAS_BETA_CELLS-0.439
- SPERMATOGENESIS-0.196
- MYOGENESIS-0.181
- ESTROGEN_RESPONSE_LATE-0.124
- XENOBIOTIC_METABOLISM-0.114
- BILE_ACID_METABOLISM-0.080
- APICAL_SURFACE-0.069
- ESTROGEN_RESPONSE_EARLY-0.031
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934840 | — | — | 0.972 |
| 2 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.960 |
| 3 | SRR934846 | — | — | 0.952 |
| 4 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.948 |
| 5 | D494D692-9EC2-429A-A0FE-696D2A152D4A | — | — | 0.943 |
| 6 | D717EAB5-3C67-4EF0-99BF-3416278BE492 | — | — | 0.940 |
| 7 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.939 |
| 8 | SRR934827 | — | — | 0.938 |
| 9 | 9BB12A25-E833-4055-8CEF-814EA5454F11 | — | — | 0.933 |
| 10 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.614 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.608 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.581 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.501 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.496 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.479 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.469 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.429 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.429 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.428 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.392 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.382 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.375 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| HYPOXIA | 0.342 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.332 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.321 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.296 | Inavolisib | — uncovered |